AstraZeneca vaccine, Ema’s decision: green light. Draghi: tomorrow we start again- Corriere.it

The vaccination plan with also the use of the AstraZeneca vaccine can start over. Even in Italy, where the prime minister Mario draghi said he will resume vaccination with this drug starting tomorrow.

The safety committee of theMother (Prac), at the end of the extraordinary meeting on research on the AstraZeneca vaccine against Covid-19 and on thromboembolic events, which in fact reached a clear scientific conclusionThe executive director of the European Medicines Agency, Emer Cooke, said at a press conference: This is a safe and effective vaccine and its benefits and the protection of people against Covid-19 and the associated risks and hospitalizations outweigh the possible risks.

Italy to resume immediately – already tomorrow from 15 – the administration of the drug. This was confirmed by the national drug agency (Aifa): After listening to the Minister of Health, the General Directorate of Prevention and the Higher Health Council, Aifa announces that the reasons behind the ban no longer exist of the vaccine batches, issued on March 15, 2021. Therefore, tomorrow, as soon as the Committee for Medicinal Products for Human Use (CHMP) issues its opinion, Aifa will proceed to revoke the ban use of the AstraZeneca vaccine, which allows a full campaign resumption vaccination from 3:00 p.m.

The AstraZeneca vaccine, as stated in the EMA note, not associated with an overall increased risk of thrombosis: Cases of thrombosis after the administration of the AstraZeneca vaccine are fewer than those that occur in the unvaccinated population, explained Sabine Straus, president of the PRAC.

As of yesterday, 7 cases of intravascular coagulation and 18 cases of thrombosis had been reported from nearly 20 million vaccinated people (25 cases in total), Straus said. Ema found no evidence of quality or batch issues. Here all the details in the in-depth analysis by the writing of Health messenger.

Updated information brochure

States can now make informed decisions, stressed the EMA, after the precautionary suspension decided by some countries (including Italy, Germany and France).

it’s more in rare events reported after the administration of the AstraZeneca vaccine – very rare, almost all among women under 55, writes the EMA in its note -, Cooke said it will be done other ideas: At the moment there is no evidence that it was the vaccine that caused them. The cases under the lens are seven in Germany, three in Italy, one in Spain, two in Norway, two in India, three in Great Britain.

Therefore, the EMA, in concluding that the safe and effective AstraZeneca vaccine and its benefits outweigh the risks, explained that consumers should be warned about the possibility of very rare thrombotic episodes. the AstraZeneca vaccine package insert needs to be updatedIt is important that the public and healthcare professionals are made aware of this information, which will allow them to mitigate these side effects.

The preventive suspension of the vaccine.

Last Monday, some EU countries, including Italy, France, Spain, Germany, Spain and Portugal, had decided to temporarily suspend the use of AstraZeneca doses as a precautionary measure after some adverse effects that occurred after the administration of the serum. Denmark, Norway, Ireland and the Netherlands had already decided on a stop.

Then other countries joined. Last Tuesday at the press conference Emer Cooke assured: We are evaluating each incident, case by case. Our experts are also meeting today (Tuesday, ed), to evaluate all the information. Experts will reach a conclusion on Thursday. And he said that the Era continued to insist that the benefits of the vaccine to prevent Covid-19, with the associated risks of hospitalization and death, outweigh the risks of these side effects. In addition, last Monday the EMA had explained that the number of total thromboembolic events in vaccinated people, it does not seem to be greater than that observed in the general population, which suggests not interrupting the vaccination campaign.